CHEK1 and head and neck cancer: Another novel CHK1 inhibitor, CCT244747, the first orally bioavailable CHK1 inhibitor, sensitized bladder and head and neck cancer cells to IR through modulation of G2/M checkpoint control, suggesting that CCT244747 may be suitable for oral administration409,410.